TITLE

Targeted therapies for CML: practical considerations and comparisons

AUTHOR(S)
Blamble, Debbie; Michaud, Laura Boenhnke
PUB. DATE
August 2008
SOURCE
Hem/Onc Today;8/10/2008, Vol. 9 Issue 14, p14
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article discusses other targeted therapies that have been approved for Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML), since the approval of imatinib. Among them are two new tyrosine kinase (TK) inhibitors, dasatinib and nilotinib. A comparison between dasatinib, imatinib and nilotinib is offered. The need to address the possibility of drug interactions when prescribing such medications is emphasized.
ACCESSION #
33463680

 

Related Articles

  • Atypical Chronic Myeloid Leukaemia with CD117-Positive Blast Cells Treated with Imatinib: A Report of Two Cases. Breccia, Massimo; Russo, Eleonora; De Propris, Maria Stefania; Frustaci, Annamaria; Alimena, Giuliana // Acta Haematologica;Oct2006, Vol. 116 Issue 3, p211 

    The article describes two cases of chronic myeloid leukemia (CML) treated with imatinib mesylate on the basis of the bright expression of c-kit on blast cells. The first case involves a 53-year-old woman who was admitted to a hospital due to itchiness and splenomegaly. The second case involves a...

  • Challenges for Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors. Oyekunle, Anthony; Klyuchnikov, Evgeny; Ocheni, Sunday; Kröger, Nicolaus; Zander, Axel R.; Baccarani, Michele; Bacher, Ulrike // Acta Haematologica;2011, Vol. 126 Issue 1, p30 

    Following the introduction of the tyrosine kinase inhibitor (TKI) imatinib in the treatment of chronic myeloid leukemia (CML) patients, the allogeneic hematopoietic stem cell transplantation (HSCT) scene in CML has changed dramatically. The number of patients receiving HSCT in first chronic...

  • Improved Drug Adherence in Patients with Chronic Myeloid Leukemia in the Chronic Phase by Switching to Second-Generation Tyrosine Kinase Inhibitors. Maeda, Yasuhiro; Okamoto, Atsushi; Kawaguchi, Shin-ichiro; Konishi, Akiko; Yamamoto, Kenta; Eguchi, Go; Kanai, Yoshitaka; Yamaguchi, Terufumi // Acta Haematologica;Nov2017, Vol. 138 Issue 3, p140 

    The article discusses the improved drug adherence in patients with chronic myeloid leukemia (CML) by switching to second-generation tyrosine kinase inhibitors (TKI). It compared the drug adherence rates from Imatinib (IM) to TKI nilotinib (NILO). It notes that adherence is a critical factor for...

  • Medication Adherence to Tyrosine Kinase Inhibitors: 2-Year Analysis of Medication Adherence to Imatinib Treatment for Chronic Myeloid Leukemia and Correlation with the Depth of Molecular Response. Santoleri, Fiorenzo; Lasala, Ruggero; Ranucci, Elena; La Barba, Gaetano; Di Lorenzo, Roberto; Vetrò, antonio; Di Bartolomeo, Paolo; Costantini, alberto // Acta Haematologica;Jun2016, Vol. 136 Issue 1, p45 

    Objective: Adherence to tyrosine kinase inhibitor treatment is a significant factor in the achievement of a good clinical response in chronic myeloid leukemia (CML). The aim of this retrospective study is to investigate 1- and 2-year medication adherence to imatinib treatment, linking adherence...

  • Switching-On Adherence in Chronic Myeloid Leukemia. Leader, Avi; Raanani, Pia // Acta Haematologica;Nov2017, Vol. 138 Issue 3, p138 

    The authors reflect on the clinical challenge in the management of chronic myeloid leukemia (CML) due to patients' nonadherence to tyrosine kinase inhibitors (TKI). They cite the retrospective study by Maeda et al. that suggests that switching medications from imatinib to nilotinib may resolve...

  • Therapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era? Trela, Ewelina; Glowacki, Sylwester; Błasiak, Janusz // ISRN Otolaryngology;2014, p1 

    Chronic myeloid leukemia (CML) results from the clonal expansion of pluripotent hematopoietic stem cells containing the active BCR/ABL fusion gene produced by a reciprocal translocation of the ABL1 gene to the BCR gene. The BCR/ABL protein displays a constitutive tyrosine kinase activity and...

  • Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders. Tsimberidou, Apostolia M.; Colburn, Dawn E.; Welch, Mary Alma; Cortes, Jorge E.; Verstovsek, Srdan; O'Brien, Susan M.; Albitar, Maher; Kantarjian, Hagop M.; Giles, Francis J. // Cancer Chemotherapy & Pharmacology;Sep2003, Vol. 52 Issue 3, p229 

    Purpose: The tyrosine kinase inhibitor imatinib mesylate inhibits the function of the Bcr-Abl oncoprotein associated with Philadelphia-positive chronic myelogenous leukemia (CML). Anagrelide suppresses megakaryocyte proliferation and differentiation. The objectives of this study...

  • Rational design of inhibitors that bind to inactive kinase conformations. Yi Liu; Gray, Nathanael S // Nature Chemical Biology;Jul2006, Vol. 2 Issue 7, p358 

    Many of the kinase inhibitors that have been developed such as the type I inhibitors target the ATP binding site of the kinase. Crystal structures of inhibitors like imatinib (STI571), BIRB796 and sorafenib are type II inhibitors revealed new binding mode that exploits additional binding site...

  • Apoptosis-Related Gene Expression Profile in Chronic Myeloid Leukemia Patients after Imatinib Mesylate and Dasatinib Therapy. Ferreira, aline Fernanda; de Oliveira, Gislane L.V.; Tognon, Raquel; Collassanti, Maria Dulce S.; Zanichelli, Maria aparecida; Hamerschlak, Nelson; de Souza, ana Maria; Covas, Dimas Tadeu; Kashima, Simone; de Castro, Fabiola attie // Acta Haematologica;May2015, Vol. 133 Issue 4, p354 

    Background/Aims: We investigated the effects of tyrosine kinase inhibitors (TKIs) on the expression of apoptosis-related genes (BCL-2 and death receptor family members) in chronic myeloid leukemia (CML) patients. Methods: Peripheral blood mononuclear cells from 32 healthy subjects and 26 CML...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics